Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advan ...

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

Global Klinefelter Syndrome Therapeutics MarketThe global Klinefelter Syndrome Therapeutics Market is projected to surpass ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.

"Selective laser trabeculoplasty should not only be considered an effective and safe alternative to medications as a ...